Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Martine L.M. Lamfers"'
Autor:
Eelke M. Bos, Elena Binda, Iris S.C. Verploegh, Eva Wembacher, Daphna Hoefnagel, Rutger K. Balvers, Anne L. Korporaal, Andrea Conidi, Esther A. H. Warnert, Nadia Trivieri, Alberto Visioli, Paola Zaccarini, Laura Caiola, Rogier van Wijck, Peter van der Spek, Danny Huylebroeck, Sieger Leenstra, Martine L.M. Lamfers, Zvi Ram, Manfred Westphal, David Noske, Federico Legnani, Francesco DiMeco, Angelo Luigi Vescovi, Clemens M.F. Dirven
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-9 (2023)
Abstract Background This Phase 1 study evaluates the intra- and peritumoral administration by convection enhanced delivery (CED) of human recombinant Bone Morphogenetic Protein 4 (hrBMP4) – an inhibitory regulator of cancer stem cells (CSCs) – in
Externí odkaz:
https://doaj.org/article/b6e88963f885415e8d912afbaecd0fc3
Autor:
Anne Kleijn, Wouter van den Bossche, Erik S. Haefner, Zineb Belcaid, Chantal Burghoorn-Maas, Jenneke J. Kloezeman, Suzan D. Pas, Sieger Leenstra, Reno Debets, Jeroen de Vrij, Clemens M.F. Dirven, Martine L.M. Lamfers
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 11-19 (2017)
The conditionally replicating oncolytic adenovirus Delta24-RGD (Ad) is currently under investigation in clinical trials for glioblastoma, including in combination with temozolomide (TMZ), the standard chemotherapy for this tumor. Previously, we showe
Externí odkaz:
https://doaj.org/article/638eb206e27f41b2bcb5dca670a9a6cd
Autor:
Rutger K. Balvers, Zineb Belcaid, Sanne K. van den Hengel, Jenneke Kloezeman, Jeroen de Vrij, Hiroaki Wakimoto, Rob C. Hoeben, Reno Debets, Sieger Leenstra, Clemens Dirven, Martine L.M. Lamfers
Publikováno v:
Viruses, Vol 6, Iss 8, Pp 3080-3096 (2014)
Oncolytic adenoviral vectors are a promising alternative for the treatment of glioblastoma. Recent publications have demonstrated the advantages of shielding viral particles within cellular vehicles (CVs), which can be targeted towards the tumor micr
Externí odkaz:
https://doaj.org/article/2668f9a73c0b4395a972d8b6dbf912a9
Autor:
Clemens M.F. Dirven, Martine L.M. Lamfers, Arnold Vulto, David T. Curiel, Winald Gerritsen, Cathy Bakker, René M. Vernhout, Charlotte E. Teunissen, Frederick F. Lang, Juan Fueyo, Jenneke J. Kloezeman, Daphna Hoefnagel, Sander Idema, Anna L. de Goede, Cor H.J. Lamers, David Noske, Victor W. van Beusechem, Anne Kleijn, Erik H.P. van Putten
Supplementary Data from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d92f39b1ed75ea06f55f53f8aaa8cbf4
https://doi.org/10.1158/1078-0432.22486506.v1
https://doi.org/10.1158/1078-0432.22486506.v1
Autor:
Clemens M.F. Dirven, Martine L.M. Lamfers, Arnold Vulto, David T. Curiel, Winald Gerritsen, Cathy Bakker, René M. Vernhout, Charlotte E. Teunissen, Frederick F. Lang, Juan Fueyo, Jenneke J. Kloezeman, Daphna Hoefnagel, Sander Idema, Anna L. de Goede, Cor H.J. Lamers, David Noske, Victor W. van Beusechem, Anne Kleijn, Erik H.P. van Putten
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07dc9dda02c9effd77bd75f9640a8c63
https://doi.org/10.1158/1078-0432.22486485
https://doi.org/10.1158/1078-0432.22486485
Autor:
Clemens M.F. Dirven, Martine L.M. Lamfers, Arnold Vulto, David T. Curiel, Winald Gerritsen, Cathy Bakker, René M. Vernhout, Charlotte E. Teunissen, Frederick F. Lang, Juan Fueyo, Jenneke J. Kloezeman, Daphna Hoefnagel, Sander Idema, Anna L. de Goede, Cor H.J. Lamers, David Noske, Victor W. van Beusechem, Anne Kleijn, Erik H.P. van Putten
Purpose:Testing safety of Delta24-RGD (DNX-2401), an oncolytic adenovirus, locally delivered by convection enhanced delivery (CED) in tumor and surrounding brain of patients with recurrent glioblastoma.Patients and Methods:Dose-escalation phase I stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15377c0d7358c6b7dd0966cad5f6a9e8
https://doi.org/10.1158/1078-0432.c.6532332.v1
https://doi.org/10.1158/1078-0432.c.6532332.v1
Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in GBM
Autor:
Federica Fabro, Nynke M. Kannegieter, Erik L. de Graaf, Karla Queiroz, Martine L.M. Lamfers, Anna Ressa, Sieger Leenstra
Glioblastoma is the deadliest brain cancer. One of the main reasons for poor outcome resides in therapy resistance, which adds additional challenges in finding an effective treatment. Small protein kinase inhibitors are molecules that have become wid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35278128375f4902e2f80c5d12c49f7d
https://doi.org/10.1101/2022.07.22.499106
https://doi.org/10.1101/2022.07.22.499106
Autor:
Giorgia Zambito, Paolo A. Netti, Joost C. Haeck, Enza Torino, Martine L.M. Lamfers, Laura Mezzanotte, Angela Costagliola di Polidoro
Publikováno v:
Cancers, Vol 13, Iss 503, p 503 (2021)
Cancers
Volume 13
Issue 3
Cancers, 13(3):503, 1-21. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Volume 13
Issue 3
Cancers, 13(3):503, 1-21. Multidisciplinary Digital Publishing Institute (MDPI)
Simple Summary Glioblastoma multiforme is the most aggressive malignant brain tumor with poor patient prognosis. The presence of the blood-brain barrier and the complex tumor microenvironment impair the efficient accumulation of drugs and contrast ag
Autor:
Erik H.P. van Putten, Anne Kleijn, Victor W. van Beusechem, David Noske, Cor H.J. Lamers, Anna L. de Goede, Sander Idema, Daphna Hoefnagel, Jenneke J. Kloezeman, Juan Fueyo, Frederick F. Lang, Charlotte E. Teunissen, René M. Vernhout, Cathy Bakker, Winald Gerritsen, David T. Curiel, Arnold Vulto, Martine L.M. Lamfers, Clemens M.F. Dirven
Publikováno v:
van Putten, E H P, Kleijn, A, van Beusechem, V W, Noske, D, Lamers, C H J, de Goede, A L, Idema, S, Hoefnagel, D, Kloezeman, J J, Fueyo, J, Lang, F F, Teunissen, C E, Vernhout, R M, Bakker, C, Gerritsen, W, Curiel, D T, Vulto, A, Lamfers, M L M & Dirven, C M F 2022, ' Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM : A Phase I Clinical Trial Including Correlative Studies ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 8, pp. 1572-1585 . https://doi.org/10.1158/1078-0432.CCR-21-3324
Clinical Cancer Research, 28, 8, pp. 1572-1585
Clinical Cancer Research, 28, 1572-1585
Clinical Cancer Research, 28(8), 1572-1585. American Association for Cancer Research Inc.
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(8), 1572-1585. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 8, pp. 1572-1585
Clinical Cancer Research, 28, 1572-1585
Clinical Cancer Research, 28(8), 1572-1585. American Association for Cancer Research Inc.
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(8), 1572-1585. American Association for Cancer Research Inc.
Purpose: Testing safety of Delta24-RGD (DNX-2401), an oncolytic adenovirus, locally delivered by convection enhanced delivery (CED) in tumor and surrounding brain of patients with recurrent glioblastoma. Patients and Methods: Dose-escalation phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e98a4f8e026196acc27eb52c8fe11327
https://research.vumc.nl/en/publications/c446737f-705c-42cd-b2f7-497eb4aee279
https://research.vumc.nl/en/publications/c446737f-705c-42cd-b2f7-497eb4aee279
Autor:
Selas T F Bots, Steve J. Cramer, Martine L.M. Lamfers, Rob C. Hoeben, Gabri van der Pluijm, Vera Kemp, Diana J. M. van den Wollenberg, Marten Hornsveld
Publikováno v:
Human Gene Therapy, 33(5-6), 275-289. Mary Ann Liebert Inc.
The use of human adenoviruses (hAds) as oncolytic agents has demonstrated considerable potential. However, their efficacy in clinical studies is generally moderate and often varies between patients. This may, in part, be attributable to variable pre-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::989d4d2d8b69e73a17fb2566df9a4b1f
https://pure.eur.nl/en/publications/4c3df4ce-533a-4f72-9e7c-f4bc66c63eaa
https://pure.eur.nl/en/publications/4c3df4ce-533a-4f72-9e7c-f4bc66c63eaa